Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03356106
Other study ID # ID11-58-12
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 16, 2016
Est. completion date December 31, 2019

Study information

Verified date December 2021
Source Ramathibodi Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label multicenter randomized-controlled trial in 3 tertiary care hospitals including Ramathibodi Hospital, Phramongkutklao Hospital and Rajavithi Hospital. The study involved screening of obstructive sleep apnea in high risk pregnancy during 1st and 2nd trimesters. Randomization to either continuous positive airway pressure (CPAP) or usual antenatal care (ANC) until delivery will be done. Efficacy of CPAP on pregnancy outcome will be analysed.


Description:

Screening for sleep disordered breathing (Respiratory disturbance index, RDI ≥ 5 events/hour) with type 2 sleep test will be performed in eligible subjects during early1st trimester (<16 weeks). Repeat sleep study will be done if the RDI in 1st trimester is less than 5. If the subjects meet the inclusion criteria without any of the exclusion criteria, randomization into either receiving CPAP treatment or usual ANC will be done. The pressure of CPAP machine is determined using autoCPAP machine algorithm at 90 percentile. Adjustment of CPAP machine is repeated at 24-28 week gestations. Subjects in both groups received standard usual care during ANC and outcomes were measured with similar case record forms.


Recruitment information / eligibility

Status Completed
Enrollment 340
Est. completion date December 31, 2019
Est. primary completion date November 30, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility High risk pregnant women attending the antenatal care at the collaborated hospitals will be eligible for the study if they meet all following inclusion criteria. Inclusion criteria (ALL criteria) 1. Singleton pregnant women age = 18 years 2. Pregnant women attending the antenatal care and intending to deliver at one of the study hospitals with gestational age < 16 weeks 3. Thai nationality with ability to use Thai language proficiently both in spoken and written language. 4. Have been diagnosed as high-risk pregnancy by Obstetricians by having any of the following conditions 1. Chronic hypertension prior to pregnancy 2. Hypertension during pregnancy before 20 weeks gestation. 3. Pre-eclampsia/gestational hypertension during recent pregnancy 4. Obesity defined by pre-pregnancy body mass index (BMI) = 27.5 kg/m2 5. History of diabetes mellitus or gestational diabetes 6. Having gestational diabetes or overt diabetes 5. Presence of snoring (either as frequent snoring =3 times/week or loud snoring) prior to or occurring during pregnancy OR respiratory disturbance index, RDI = 5 events/hour by type 2 sleep testing at either point of testing during early pregnancy (0-16 GA week) or late pregnancy (GA 24-28week ). 6. Sign written informed consent Exclusion Criteria: 1. Subjects' unwillingness to participate in the study at any time of the study. 2. Subject with significant medical conditions such as immunocompromised status, chronic infection (HIV infection, tuberculosis), chronic lung and cardiac conditions, chronic renal failure, thyroid disease, or neuromuscular disease. 3. Subjects with extremely severe obstructive sleep apnea (RDI =30) or with significant O2 desaturation <80% during sleep that might have potential benefit from the CPAP treatment. 4. Subject with known obstructive sleep apnea and currently on CPAP treatment

Study Design


Intervention

Device:
Continuous positive airway pressure (CPAP)
A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep

Locations

Country Name City State
Thailand Phramongkutklao Hospital Bangkok
Thailand Rajavithi Hospital Bangkok
Thailand Ramathibodi hospital Bangkok

Sponsors (3)

Lead Sponsor Collaborator
Ramathibodi Hospital National Research Council of Thailand, The Development Potentials of Thai People Project, Ramathibodi hospital

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of blood pressure Difference of daytime systolic and diastolic blood pressure between 2 groups (mmHg) During 24-28 weeks gestation
Primary Measurement of blood pressure Difference of daytime systolic and diastolic blood pressure between 2 groups (mmHg) During 32-34 weeks gestation
Primary Measurement of blood pressure Difference of daytime mean blood pressure between 2 groups (mmHg) During 24-28 weeks gestation
Primary Measurement of blood pressure Difference of daytime mean blood pressure between 2 groups(mmHg) During 32-34 weeks gestation
Primary Measurement of blood pressure Difference of daytime mean blood pressure between 2 groups (mmHg) During 18-20 weeks gestation
Primary Measurement of blood pressure Difference of daytime systolic and diastolic blood pressure between 2 groups (mmHg) During 18-20 weeks gestation
Secondary 24-hour ambulatory blood pressure monitoring Using non-invasive technique from pulse transit time (SomnoTouch NIBP) (mmHg) measured twice during 24-28 week gestation, and 32-34 week gestation
Secondary 24-hour ambulatory blood pressure monitoring Using non-invasive technique from pulse transit time (SomnoTouch NIBP) (mmHg) measured twice during 32-34 week gestation
Secondary Incidence of pregnancy induced hypertension (composite outcome1) Incidence of hypertensive disorder of pregnancy During pregnancy until delivery
Secondary Incidence of hypertensive disorder of pregnancy or preterm labor or fetal growth restriction or emergency Cesarean section (composite outcome2) Incidence of hypertensive disorder of pregnancy or preterm labor or fetal growth restriction or emergency Cesarean section During pregnancy until delivery
Secondary Incidence of preterm labor or fetal growth restriction or severe pre-eclampsia or eclampsia or death (composite outcome3) Incidence of preterm labor or fetal growth restriction or severe pre-eclampsia or eclampsia or death During pregnancy until delivery
Secondary Fasting plasma glucose Fasting plasma glucose (mg/dL) during 24-28 weeks gestation
Secondary Fasting plasma glucose Fasting plasma glucose (mg/dL) during 32-34 weeks gestation
Secondary Oral glucose tolerance test (OGTT) Oral Glucose Tolerance Test (OGTT) (mg/dL) during 24-28 weeks gestation
Secondary Fetal ultrasound results Fetal growth (grams) During 24-28 weeks gestation
Secondary Fetal ultrasound results Fetal growth (grams) During 32-34 weeks gestation
Secondary Fetal ultrasound results Uterine Doppler arterial blood flow During 18-20 weeks gestation
Secondary Fetal ultrasound results Uterine Doppler arterial blood flow During 24-28 weeks gestation
Secondary Fetal ultrasound results Uterine Doppler arterial blood flow During 32-34 weeks gestation
Secondary Neonatal birthweight Neonatal birthweight (grams) at delivery
Secondary APGAR score The Apgar scale is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. The five criteria are summarized using words chosen to form an acronym (Appearance, Pulse, Grimace, Activity, Respiration). Scores 7 and above are generally normal, 4 to 6 fairly low, and 3 and below are generally regarded as critically low. at 1 minute and 5 minutes after birth
Secondary Neonatal length of stay in hospital Neonatal length of hospital stay (days) after birth until the newborn is discharged from the hospital Through study completion up to 24 weeks
Secondary Neonatal ICU admission rate Neonatal ICU admission rate (%) after birth Through study completion up to 24 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03605329 - Evaluation of the Severity of Cardiovascular Autonomic Neuropathy in Type 1 Diabetic Patients With OSAS N/A
Completed NCT04912635 - Evaluation of a Health Dashboard Intervention to Improve Engagement With CPAP Therapy in PAP-Naïve Patients: Project Neo N/A
Not yet recruiting NCT05939934 - Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal N/A
Enrolling by invitation NCT02290236 - Monitored Saturation Post-ICU N/A
Completed NCT02088723 - Testing the Elevation as Sleep Apnea Treatment N/A
Terminated NCT02269774 - Origin of Premature Atrial Beats Induced by Simulated Obstructive Sleep Apnea N/A
Completed NCT02261857 - 3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea Early Phase 1
Completed NCT01943708 - Novel Auto-continuous Positive Airway Pressure (CPAP) Validation Phase 3
Completed NCT01181570 - Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Phase 4
Completed NCT00273754 - The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA). Phase 2
Recruiting NCT02166879 - Undetected Sleep Apnea in the Postanesthesia Acute Care Unit (PACU)
Recruiting NCT04963192 - Integrated Management of Chronic Respiratory Diseases N/A
Completed NCT04846400 - Pilot Study of a Self-Supporting Nasopharyngeal Airway in Hypotonia N/A
Completed NCT05056766 - How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolved According to Propulsion: Control With Each mm of Advancement
Recruiting NCT04314492 - Intracapsular Tonsillectomy in the Treatment of Obstructive Sleep Apnea in Adults N/A
Completed NCT05175287 - OSA (oRisk of Obstructive Sleep Apnea and Traffic Accidents Among Bus Drivers in Ecuador: is There a Significant Association
Active, not recruiting NCT03431038 - Cross-sectional Study of Prevalence Rate of Abdominal Aortic Aneurysm in OSAHS Patients From BTCH N/A
Enrolling by invitation NCT03075787 - Cardiovascular Variability and Heart Rate Response Associated With Obstructive Sleep Apnea N/A
Completed NCT03300037 - HYpopnea and Apnea Detection and Treatment Performance of a New cardiOreSpiratory Holter Monitor N/A
Recruiting NCT06097949 - AcuPebble to Remotely Monitor Patients With OSA on CPAP Therapy